EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Soluble Guanylate Cyclase Stimulator, BAY41‐8543: A Promising Approach for the Treatment of Chronic Heart Failure Caused by Pressure and Volume Overload

Adriana Martišková, Matúš Sýkora iD, Natália Andelová iD, Miroslav Ferko, Olga Gawrys, Katarína Andelová, Petr Kala, Luděk Červenka, Barbara Szeiffová Bačová iD

Pharmacology Research & Perspectives · 2025

DOI: 10.1002/prp2.70087 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacology Research & Perspectives, 2025. Verfasst von Adriana Martišková und 8 weiteren Autor:innen. Beteiligte Einrichtung: Centre of Experimental Medicine, Slovak Academy of Sciences, Institute for Heart Research, Bratislava, Slovakia. Hauptthemen laut MEDLINE: Soluble Guanylyl Cyclase, Heart Failure, Pyrimidines, Pyrazoles. Die Arbeit nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of the Czech Republic, Slovak Research and Development Agency, Scholarships for Excellent R2-R4 Researchers.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Heart failure (HF) is a leading cause of morbidity and mortality, often driven by prolonged exposure to pathological stimuli such as pressure and volume overload. These factors contribute to excessive oxidative stress, adverse cardiac remodeling, and dysregulation of the nitric oxide‐soluble guanylate cyclase‐cyclic guanosine monophosphate (NO‐sGC‐cGMP) signaling pathway. Given the urgent need for effective treatments, this study investigated the potential of sGC stimulators to mitigate HF progression. We utilized male hypertensive Ren‐2 transgenic (TGR) rats and a volume‐overload HF model induced by an aortocaval fistula (ACF). Rats received the sGC stimulator BAY 41–8543 (3 mg/kg/day) for 30 weeks, while normotensive Hannover Sprague–Dawley rats served as controls. At the study endpoint (40 weeks of age), left ventricular tissue was analyzed using mass spectrometry, Western blotting, and histological assessment. TGR rats treated with sGC stimulators exhibited a significant increase in key antioxidant proteins (SOD1, CH10, ACSF2, NDUS1, DHE3, GSTM2, and PCCA), suggesting enhanced resistance to oxidative stress. However, sGC stimulator treatment also upregulated extracellular matrix remodeling markers (MMP‐2, TGF‐β, and SMAD2/3), which are typically associated with fibrosis. Despite this, Masson's trichrome staining revealed reduced collagen deposition in both TGR and TGR‐ACF rats receiving sGC stimulators. Notably, all untreated TGR‐ACF rats succumbed before the study endpoint, preventing direct assessment of sGC stimulator effects in advanced HF. These findings highlight the therapeutic potential of sGC stimulators in HF, particularly through their antioxidant effects. However, their concurrent influence on fibrosis warrants further investigation to optimize treatment strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Soluble Guanylyl CyclaseHeart FailurePyrimidinesPyrazolesGuanylyl Cyclase C AgonistsAnimalsMaleRatsRats, Sprague-DawleyRats, TransgenicDisease Models, AnimalOxidative StressVentricular RemodelingMorpholines

Stichwörter der Autor:innen

heart failure with reduced ejection fractionreactive oxygen/nitrogen speciesrenin‐angiotensin systemsoluble guanylate cyclase stimulator

Substanzen

Soluble Guanylyl CyclaseBAY 41-8543PyrimidinesPyrazolesGuanylyl Cyclase C AgonistsMorpholines

Autor:innen und Institutionen

  • Centre of Experimental Medicine, Slovak Academy of Sciences, Institute for Heart Research, Bratislava, Slovakia.
  • Centre for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.

ORCID-Profile: Matúš Sýkora, Natália Andelová, Barbara Szeiffová Bačová

Förderung

  • Ministry of the Czech Republic
  • Slovak Research and Development Agency
  • Scholarships for Excellent R2-R4 Researchers
  • National Institute for Research of Metabolic and Cardiovascular Diseases
  • Scientific Grant Agency of the Ministry of Education, Research, Development and Youth of the Slovak Republic and Slovak Academy of Sciences
  • Agentúra na Podporu Výskumu a Vývoja

Zitieren

APA

Martišková, A., Sýkora, M., Andelová, N., Ferko, M., Gawrys, O., Andelová, K., Kala, P., Červenka, L., & Szeiffová Bačová, B. (2025). Soluble Guanylate Cyclase Stimulator, BAY41‐8543: A Promising Approach for the Treatment of Chronic Heart Failure Caused by Pressure and Volume Overload. Pharmacology Research & Perspectives. https://doi.org/10.1002/prp2.70087

Vancouver

Martišková A, Sýkora M, Andelová N, Ferko M, Gawrys O, Andelová K, et al. Soluble Guanylate Cyclase Stimulator, BAY41‐8543: A Promising Approach for the Treatment of Chronic Heart Failure Caused by Pressure and Volume Overload. Pharmacology Research & Perspectives. 2025. doi:10.1002/prp2.70087

BibTeX
@article{Martikov2025,
  author = {Martišková, Adriana and Sýkora, Matúš and Andelová, Natália and Ferko, Miroslav and Gawrys, Olga and Andelová, Katarína and Kala, Petr and Červenka, Luděk and Szeiffová Bačová, Barbara},
  title = {Soluble Guanylate Cyclase Stimulator, BAY41‐8543: A Promising Approach for the Treatment of Chronic Heart Failure Caused by Pressure and Volume Overload},
  journal = {Pharmacology Research & Perspectives},
  year = {2025},
  doi = {10.1002/prp2.70087}
}
Kostenlos starten →